NASDAQ:CYTR LadRx (CYTR) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CYTR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.1052-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LadRx alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About LadRx Stock (NASDAQ:CYTR)LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 CYTR Stock News HeadlinesMay 17, 2023 | investing.comLadRx (LADX) Earnings Dates & ReportsMarch 29, 2023 | stockhouse.comLadRx Highlights Patent Issued for Its LADR TechnologyApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinOctober 5, 2022 | finance.yahoo.comLadRx Corporation Announces OTCQB Ticker Change to LADXSeptember 23, 2022 | finance.yahoo.comCytRx Corporation Relaunches as LadRx CorporationSeptember 8, 2022 | seekingalpha.comEuropean patent office awards CytRx patent for LADR platformSeptember 7, 2022 | finance.yahoo.comEuropean Patent Office Awards CytRx Key PatentAugust 3, 2022 | marketwatch.comTemperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinAugust 2, 2022 | thestreet.comWhiplash: S&P Veers to All-Time High Before CrashingMay 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common StockMay 18, 2022 | marketwatch.comKinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of valueSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CYTR CUSIPN/A CIKN/A Webwww.cytrx.com Phone(310) 826-5648FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free FloatN/AMarket Cap$4.14 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesStephen SnowdyChief Executive OfficerJohn Y. CalozChief Financial Officer, Treasurer & Senior VPFelix KratzVice President-Drug DiscoveryCristina NewmanSecretaryKey CompetitorsFirst Trust IPOX Europe Equity Opportunities ETFNASDAQ:FPXEGlobal X Education ETFNASDAQ:EDUTFirst Trust Brazil AlphaDEX FundNASDAQ:FBZFirst Trust China AlphaDEX FundNASDAQ:FCAFirst Trust Germany AlphaDEX FundNASDAQ:FGMView All Competitors This page (NASDAQ:CYTR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
